Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000521619 | SCV000618078 | likely pathogenic | not provided | 2017-09-06 | criteria provided, single submitter | clinical testing | The V705D variant has previously been reported as homozygous in an individual with mitochondrial trifunctional protein deficiency (Djouadi et al., 2015). This individual had significantly reduced long chain fatty acid oxidation in fibroblasts (Djouadi et al., 2015). The V705D variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The V705D variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved across species, and in silico analysis predicts this variant is probably damaging to the protein structure/function. In summary, this variant is likely pathogenic; however, the possibility that it is benign cannot be excluded. |
Counsyl | RCV000674004 | SCV000799273 | uncertain significance | Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency | 2018-04-11 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000674004 | SCV004191751 | likely pathogenic | Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency | 2023-10-13 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000674004 | SCV002076493 | likely pathogenic | Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency | 2020-08-17 | no assertion criteria provided | clinical testing |